TCR2 THERAPEUTICS INC. (TCRR) [Rocket]

Overview

TCR2 THERAPEUTICS INC. (TCRR)

Add to portfolio

1m \| 3m \| 6m \| 1y \| 2y \| 5y \| 10y

Recent News + Filings (All items)

Date Filed	Type	Description
06/12/2023	15-12G	Form 15-12G - Securities registration termination [Section 12(g)]:
06/01/2023	POS AM	Form POS AM - Post-Effective amendments for registration statement:
06/01/2023	POS AM	Form POS AM - Post-Effective amendments for registration statement:
06/01/2023	POS AM	Form POS AM - Post-Effective amendments for registration statement:
06/01/2023	S-8 POS	Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
06/01/2023	S-8 POS	Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
06/01/2023	S-8 POS	Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:

Revenue Mix by Segment

Financial Summary (All financials)

In millions, except per share items	Dec-31-22	Dec-05-22	Dec-31-21	Dec-05-21	Dec-31-20	Dec-31-19	Dec-31-18	Dec-31-17
Revenues	0.0	98.6	0.0	73.6	0.0	0.0	0.0	9.6
Revenue growth		34.1%					-100.0%	24.5%
Cost of goods sold	0.0	153.5	0.0	99.7	0.0	0.0	0.0	13.2
Gross profit	0.0	-54.9	0.0	-26.2	0.0	0.0	0.0	-3.6
Gross margin		-55.6%		-35.6%				-37.7%
Selling, general and administrative	153.5		99.7		68.7
Research and development						37.5	19.7
General and administrative		24.4		22.5		13.9	6.8	3.6
EBIT	-119.2	-153.5	-95.6	-99.7	-65.2	-51.4	-26.5	-13.2
EBIT margin		-155.6%		-135.6%				-137.7%
Pre-tax income	-151.6	-151.6	-99.5	-99.5	-67.0	-47.5	-24.3	-13.1
Income taxes	0.3	0.3	0.3	0.3	0.2	0.1	0.0	0.0
Tax rate							0.0%	0.0%
Net income	-151.8	-151.8	-99.8	-99.8	-67.1	-97.5	-61.5	0.0
Net margin		-153.9%		-135.6%				-0.2%

Diluted EPS	($3.93)	($3.93)	($2.63)	($2.63)	($2.40)	($4.62)	($98.53)	($39.94)
Shares outstanding (diluted)	38.6	38.6	37.9	37.9	28.0	21.1	0.6	0.0

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.